While highly active antiretroviral therapy (HAART) decreases long-term morbidity and mortality, its short-term effect on hospitalization rates is unknown. The primary objective of this study was to determine hospitalization rates over time in the year after HAART initiation for virological responders and nonresponders.
Introduction
In the short term after starting highly active antiretroviral therapy (HAART), HIV-infected patients may have an increased risk of serious illness as a result of an immune reconstitution inflammatory syndrome (IRIS), a traditional opportunistic infection (OI), or an adverse drug reaction. While HAART is known to decrease hospitalization rates and mortality in the long term [1] [2] [3] [4] [5] [6] [7] , the time at which hospitalization risk declines during the weeks to months immediately following HAART initiation is not clear.
In studies in high-income countries conducted since the advent of HAART in 1996, AIDS-defining illnesses (ADIs) and non-ADI infections have been the most frequent reasons for hospital admission [1, 4, 6, [8] [9] [10] [11] . The next most common categories of admitting diagnoses have varied among mental illness, gastrointestinal and hepatic disease, and cardiovascular disease. Studies have compared hospitalization rates for these disease categories in the several years prior to the advent of HAART vs. the several years after its advent among cohorts of patients, not all of whom were prescribed HAART [1, 4, 5, [12] [13] [14] [15] [16] [17] . These studies did not determine changes in an individual's risk of serious illness within these disease categories in the weeks to months immediately after initiating HAART.
Our main objective was to measure the rates of all-cause hospitalizations over time in the year after HAART initiation using an urban clinical cohort of HAART-naïve, HIV-infected patients. To assess the effect on hospitalization rates produced by having a significant virological response to HAART, we compared hospitalization rates in virological responders and nonresponders. We examined causes of hospitalization by diagnostic category.
Methods

Population
All patients who engage in HIV continuity care with the Johns Hopkins AIDS service are offered enrolment in the observational Johns Hopkins HIV Clinical Cohort (JHHCC). Fewer than 1% of patients have refused [18] . As part of this study, trained abstractors extract demographic, pharmaceutical and hospitalization data from patient charts at 6-month intervals. Laboratory data are retrieved directly from the hospital laboratory system. The JHHCC is approved by the Institutional Review Board of the Johns Hopkins School of Medicine. All HAART-naïve patients initiating HAART (previous antiretroviral use was allowed) between 1 January 1997 and 31 December 2006 were considered for inclusion in this analysis.
Exposure variables
HAART was defined as any combination of at least three drugs which included at least two classes selected from the nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) classes. CD4 cell count and HIV-1 RNA level at HAART initiation were defined as the clinical measurements on the day of HAART initiation or, if not available, the closest value prior to HAART initiation within 90 days. For purposes of analysis, race/ethnicity was categorized as African American and non-African American and HIV risk factor as injecting drug use (IDU) and non-IDU. Calendar time for the date of HAART initiation was categorized as 1997-1998, 1999-2002 and 2003-2006 , reflecting milestones in antiretroviral development (Food and Drug Administration approval of efavirenz in September 1998 and of atazanavir in June 2003).
Virological and CD4 responses to HAART were determined using the single measurements made between 120 and 180 but closest to 180 days after HAART initiation. Virological responders were defined as having a decrease in HIV-1 RNA of ! 1 log 10 HIV-1 RNA copies/mL or suppression below the detection limit of the assay. Their HIV-1 RNA levels may subsequently have risen after 180 days. Nonresponders did not achieve a drop in HIV-1 RNA of ! 1 log 10 copies/mL at 180 days. For analysis purposes, CD4 response was categorized as being above or below the median change in CD4 seen among virological responders. Of the 1685 patients initially considered for inclusion, 300 were excluded because of insufficient virological data.
Outcome variables
Number of hospital admissions per time period was the primary study outcome. Counts of distinct hospital admission dates were obtained, beginning with the period from 180 days prior to HAART initiation to the day of HAART initiation. Patients were then followed for 365 days after HAART initiation, with hospitalization counts assessed in time periods of 1-45, 46-90, 91-180 and 181-365 days after initiation. For persons enrolling o180 days prior to HAART initiation, the clinic enrolment date was the start of observation. Observation ended at the sooner of (1) 365 days after HAART initiation, (2) death, (3) regimen change (including complete HAART discontinuation or any change from the initial regimen except for dosing changes), or (4) study discontinuation as a result of voluntary withdrawal or loss to follow-up.
The primary reason for each hospitalization was assessed through International Classification of Diseases, Ninth Revision (ICD-9) codes and physician chart abstraction. Hospitalizations related to clinical trials (140) were excluded from all analyses. Using a method that has twice been validated in our cohort with over 95% accuracy compared with chart review [5, 15] , the first of the top three ICD-9 codes that was neither 042 (AIDS) nor 112.0 (thrush) was defined as the primary diagnosis. Using Clinical Classifications Software (CCS) developed by the Agency for Healthcare Research and Quality [19] , the primary ICD-9 code was classified into one of 17 first-level categories: infectious; neoplastic; endocrine, nutritional, metabolic, or immune; haematological; psychiatric (including substance abuse); neurological; cardiovascular; pulmonary; digestive and hepatic; renal (including genitourinary); pregnancyrelated; dermatological; musculoskeletal and rheumatological; congenital; perinatal; traumatic; and other. The CCS assigns many infectious conditions to a first-level organ system category rather than to the infectious category. Additional CCS levels were used to reassign the following to the infectious category: central nervous system infection; infection of the eye; otitis media; endocarditis; respiratory infection; intestinal infection; anal and rectal conditions; peritonitis and intestinal abscess; urinary tract infections; inflammatory conditions of the genitals; skin and subcutaneous tissue infections; infective arthritis and osteomyelitis; infection and inflammation of an internal prosthesis; postoperative infection. Finally, a separate category for ADI was generated, and appropriate admissions were reassigned according to individual ICD-9 codes [20] . Any non-first admission for bacterial pneumonia (ICD-9 codes ! 481 and o483) was categorized as an ADI.
IRIS was defined according to established criteria [21, 22] as signs or symptoms that were consistent with an inflammatory and/or atypical presentation of an OI or malignancy, were not medication side effects, and occurred in a virological responder within 6 months of HAART initiation. The pathogen or process had to be identified microbiologically or histopathologically. To determine IRIS hospitalizations, chart abstraction specifically for IRIS was undertaken on records of all virological responders admitted within 6 months of HAART initiation. For purposes of analysis, all IRIS cases were considered ADIs.
Analysis
Baseline characteristics of responders and nonresponders were compared using the w 2 or Wilcoxon rank-sum test.
Negative binomial regression was used to examine hospitalization rates, which were calculated per 100 person-years (PY) by dividing number of hospital admissions within a time period for each subject by accrued person-time based on the exact day of a subject's entry or exit into observation. Crude hospitalization rates for responders and nonresponders in various time periods were estimated in a regression model which included response status, time periods before (the 180 days prior) and after initiation (1-45, 46-90, 91-180 and 181-365 days) and the interaction terms between these variables. Each baseline exposure was evaluated with bivariate regression. The final multivariate model included all exposure variables for which the bivariate P was o0.2. A population-averaged approach employing generalized estimating equations was used to estimate regression coefficients and obtain robust standard errors adjusted for the correlated nature of repeated admissions among patients [23] . P-values o0.05 were considered statistically significant. STATA 10.0 (StataCorp LP, College Station, TX, USA) was used for all analyses [24] .
Sensitivity and subgroup analyses
Over 75% of IRIS cases in our cohort occurred in persons with initiation CD4 counts o100 cells/mL [25] . Therefore, a sensitivity analysis was performed by restricting the analysis to subjects with initiation CD4 counts o100 cells/mL. A relatively brief period of adherence to HAART may produce a 1 log 10 copies/mL drop in HIV-1 RNA level. Therefore, a second sensitivity analysis was performed by defining virological response as a ! 2 log 10 copies/mL drop in HIV-1 RNA at 6 months after initiation. Because subjects censored for regimen change may have had high hospitalization rates because of drug toxicity, we performed a third sensitivity analysis by excluding subjects thus censored. The 604 subjects reporting IDU as an HIV risk factor make up a significant portion (44%) of our study cohort. We performed a subgroup analysis of hospitalization rates among these subjects.
Results
The analysis was performed on 1385 HAART-naïve patients, almost three-quarters of whom (1010) Eighty-eight per cent of responders and 71% of nonresponders were observed 4180 days after HAART initiation and contributed to each post-initiation time period (Po0.001; Fig. 1 ). Seventy-nine per cent of responders and 61% of nonresponders were observed for 365 days without censoring. Responders were censored because of regimen change less frequently than nonresponders (13% vs. 34%; Po0.001). There was no significant difference in censoring because of withdrawal/ loss to follow-up (7% of responders and 4% of nonresponders; P 5 0.06) or death (1% vs. 2%; P 5 0.29). Among the 1385 subjects, there were 23 deaths within 365 days following HAART initiation. There were no significant differences in death rates across time periods or for responders vs. nonresponders within time periods. For the 6-month period prior to HAART initiation, 94% of responders and 96% of nonresponders contributed some observation time; 50% of responders and 68% of nonresponders contributed a full 180 days (Po0.001).
The all-cause hospitalization rate in virological responders during the first 45 days following HAART initiation Hospitalizations after starting HAART 291 was 75.1/100 PY [95% confidence interval (CI) 58.2, 96.8/ 100 PY; Fig. 1 ]. This was comparable to their pre-HAART rate of 78.8/100 PY (95% CI 66.5, 93.4/100 PY). For responders, the crude hospitalization rate declined statistically significantly during the 46 to 90-day time period, with a relative rate (RR) vs. the first 45 days of 0.71 (95% CI 0.51, 0.98). From 90 days to the end of the year, the hospitalization rate for responders stabilized at near 45/100 PY (RR for days 91-180 vs. the first 45 days, 0.56; 95% CI 0.40, 0.78). For nonresponders, there was no statistically significant change in all-cause hospitalization rates across time periods, with the point estimates ranging from 78.7 to 99.7/100 PY (Fig. 1) . Fewer than half of all subjects (34% of responders and 46% of nonresponders; Po0.001) were ever hospitalized over the entire period beginning 180 days before HAART initiation to 365 days afterwards.
In multivariate analysis (Table 2) , responders' hospitalization rates retained an identical pattern of statistically significant decrease in later time periods vs. earlier periods (RR 0.59; 95% CI 0.42, 0.82 for responders in days 91-180 vs. days 1-45). Having an increase in CD4 count of at least 101 cells/mL (the median increase in CD4 count in virological responders) had a borderline association with a decreased risk of hospitalization (RR 0.83; 95% CI 0.67, 1.03). Additional factors significantly associated with hospitalization included being a nonresponder in the 91-180 day (RR vs. responders 2.14; 95% CI 1.41, 3.25) and 181-365 day (RR vs. responders 1.43; 95% CI 1.00, 2.04) time periods; female gender; African American race; IDU; and lower CD4 cell count at HAART initiation.
Hospitalization rates for the seven diagnostic categories with the highest rates are shown in Fig. 2 . Non-ADI infections (the three most frequent individual diagnoses being pneumonia, unspecified organism; lower limb cellulitis; and acute/subacute bacterial endocarditis) and ADIs (pneumocystosis, cryptococcosis and candidal esophagitis) were consistently the most common reasons for admission across all time periods for both responders and nonresponders. Psychiatric illness [major depression, recurrent episode; depressive disorder, not elsewhere classified (NEC); and drug-induced mood disorder] was the third most common category and was followed by gastrointestinal and hepatic disease (acute pancreatitis; chronic pancreatitis; and cirrhosis of the liver, NEC); cardiovascular disease (hypertensive end-stage chronic kidney disease; venous thrombosis, NEC; and cerebral artery occlusion with infarct); endocrine, nutritional, metabolic or immune disease (hypovolaemia, cachexia, and hypercalcaemia); and renal disease (acute renal failure, NEC; chronic renal failure; and lower nephron nephrosis).
For responders, hospitalizations as a result of ADI and non-ADI infections revealed statistically significant decreases by the period starting 90 days after HAART initiation (Fig. 2a) . In the 1-45 day period, IRIS hospitalizations (rate 10.9/100 PY; 95% CI 5.6, 21.1/100 PY) accounted for over half of the admissions in the ADI category and comprised 13% of all admissions among responders. For nonresponders (Fig. 2b) , there was no statistically significant decrease compared with day 1-45 rates in any category of admissions, although rates for ADI approached significance in the 91-180-and 181-365-day time periods (P 5 0.11 and 0.14, respectively).
In each of four sensitivity/subgroup analyses, the pattern of relative hospitalization rates over time after HAART initiation for responders and nonresponders was identical to the pattern in the primary analysis. The first sensitivity analysis, which was restricted to subjects with HAART initiation CD4 counts o100 cells/mL, revealed qualitatively higher all-cause hospitalization rates than the primary analysis (responders' rates ranged from 50.3 to 137.9/100 PY and nonresponders' from 77.7 to 166.7/100 PY). The other two sensitivity analyses consisted of (1) defining virological response by a ! 2 log 10 copies/mL drop in HIV-1 RNA at 6 months, and (2) responders and 34% of nonresponders) who would have been censored for HAART regimen change. All-cause hospitalization rates in both of these sensitivity analyses were similar to rates in the primary analysis. The subgroup (44%) of subjects reporting IDU as an HIV risk factor had qualitatively higher all-cause hospitalization rates than the full cohort, with responders ranging from 55.4 to 99.7/100 PY and nonresponders from 82.4 to 116.5/100 PY. Significant values are shown in bold. *In a multivariate model (not shown) which included CD4 cell count and use of PCP and MAC prophylaxis variables, relative hospitalization rates over time after HAART initiation were not significantly affected. As lower CD4 cell counts were highly associated with use of prophylaxis, and because CD4 cell count was felt to cause the use of prophylaxis, PCP prophylaxis and MAC prophylaxis were not included in the final multivariate model reported above. w Multivariate Po0.05 for responders vs. nonresponders within the 91-180 and 181-365 day time periods. CI, confidence interval; HAART, highly active antiretroviral therapy; IDU, injecting drug use; MSM, men who have sex with men; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PCP, Pneumocystis pneumonia; MAC, Mycobacterium avium complex.
Discussion
Our study makes several important findings. First, the hospitalization rate of virological responders appeared stable at near the pre-HAART initiation rate for 45 days and then fell substantially before reaching a plateau after 90 days. This pattern of relative rates remained similar in a multivariate model adjusting for baseline CD4 cell count, CD4 cell count response to HAART, and other potential confounders. Hospitalization rates for ADIs and non-AIDSdefining infections appeared to be the primary reasons for the overall change between 45 and 90 days after HAART initiation. The overall hospitalization rate, regardless of HAART use or nonuse, for patients in our urban clinical cohort during the years covered by this analysis was approximately 44/ 100 PY (data not shown). The hospitalization rate of virological responders reached a comparable level around 90 days after HAART initiation. For persons who achieve and maintain complete virological suppression, it is possible that the hospitalization rate would be appreciably lower. Notably, 44/100 PY is consistent with rates seen in several other cohort studies in which all-cause hospitalization rates since 1997 ranged from 11 to 49/100 PY [1, 6, 8, 10, 26] . Our high rate may be due to our relatively large proportion of IDUs [6] .
In a Vancouver cohort, Fielden et al. [27] found that patients who were ! 95% adherent to HAART (and thus may have been virological responders) were half as likely as poorly adherent patients to be hospitalized during 2 years after HAART initiation. Our findings indicate that the difference in hospitalization risk between virological responders and nonresponders starts to occur at 45 days after HAART initiation, may then plateau after 90 days, and w indicates Po0.05 for the RR vs. the 180 days prior to HAART initiation, which was used as the referent for cardiovascular admissions among nonresponders as there were no admissions for this group during days 1-45. Inf, infection; Psych, psychiatric; GI, gastrointestinal; CV, cardiovascular; End/Met, endocrine, nutritional, metabolic or immune.
is independent of having a large CD4 increase after HAART initiation.
The decreases in hospitalizations as a result specifically of ADIs and non-ADI infections among virological responders indicate that much of the clinical benefit of immune reconstitution may occur between 45 and 90 days after HAART initiation. Furthermore, this benefit may be independent of having a large increase in absolute CD4 cell count after HAART initiation. The initial redistribution of mature CD4 cells from lymphoid tissue to peripheral blood tapers within approximately the same 45-to 90-day time period [28] [29] [30] . Clinical benefit may thus appear once an effective repertoire of mature CD4 cells reaches the periphery. Although the number of events was small, the possibility of decreased rates of ADI admissions for nonresponders after 90 days of HAART suggests a possible protective effect even in the absence of a virological response at 6 months.
Studies have indicated possible increases in liver-related and cardiovascular illnesses since the advent of HAART [4] [5] [6] 31, 32] . There have been conflicting results regarding whether cardiovascular risk occurs within a few months or after years of HAART exposure [31, 32] . Among virological responders in our study, there was no evidence of increased hepatic or cardiovascular hospitalization rates during the first year after HAART initiation. There was a suggestion that nonresponders (who may have had a brief virological response which then terminated prior to 6 months) had an increased risk of gastrointestinal/liver and cardiovascular illnesses, although numbers of events are too small to be conclusive.
IRIS led to 413% of all admissions among responders in the first 45 days. Making a diagnosis of IRIS is often complicated and costly as new infections must be considered and ruled out. Previous studies have shown that 20-25% of persons starting HAART will experience an IRIS event, not all of which lead to hospitalization [33, 34] . Using the cases within this study, we have previously analysed predictors of IRIS and found boosted PIs, CD4 nadir o100 cells/mL, and HIV-1 RNA decrease 42.5 log 10 -copies/mL following initiation to be independently associated with IRIS [25] .
Calendar era made no appreciable difference to risk of hospitalization during the year following HAART initiation in our analysis. Despite US public health efforts, persons in recent years have enrolled for HIV care at similarly advanced levels of immune compromise as in 1998 and earlier [18, 35] . Our results indicate that, until more patients initiate HAART at higher CD4 cell counts, there will continue to be a substantial hospitalization burden in the several weeks after HAART initiation. Hospitalization costs contribute a significant portion of overall societal costs for HIV care [36, 37] . There is thus an economic as well as a medical justification for further expanding efforts to promote earlier engagement of HIV-infected persons in medical care.
Consistent with studies examining overall HIV-related hospitalizations, predictors of hospitalization risk in our multivariate analysis included lower CD4 cell count at HAART initiation, female gender, African American race and IDU [1, 5, 6, [9] [10] [11] 26] . Rates of OI prophylaxis indicated by CD4 cell count criteria (94% and 87%, respectively, for Pneumocystis and M. avium) exceed rates reported in national surveys [38, 39] and did not affect the overall pattern of hospitalization rates we found.
There are several potential limitations to this analysis. It is based on data from a single clinic population which has a high proportion of African Americans and IDUs. Although our results may not generalize to all HIV-infected populations, they are likely to be applicable to many urban settings. A previous comparison of hospitalizations captured in our database vs. state-wide hospital insurance claims revealed that 84% of all hospital admissions occur in our hospital [5] . There were no statistically significant differences in hospitalization at our facility vs. outside facilities with regard to gender, HIV risk factor, and race/ ethnicity. While our observed hospitalization rates may thus be underestimates, our estimated RRs are probably accurate. Use of ICD-9 codes to ascertain primary reason for admission has obvious limitations compared with prospective event capture. However, our method has been well validated in our cohort against physician chart review. While only a quarter of our cohort were nonresponders, it is surprising that almost two-thirds of these patients did not have a regimen change prior to 1 year after initiation. This does not represent optimal care, and we do not know the reasons why this happened, although we suspect patient preference to keep trying with a prescribed regimen may have been a factor. We do not have data on adherence to HAART and could not include this in our analyses. However, studies evaluating the association between selfreported adherence and plasma HIV-1 RNA levels have shown inconsistent results. Change in HIV-1 RNA level at 6 months is the Food and Drug Administration recommended primary endpoint for drug trials [40] .
In sum, our analysis indicates that virological responders continue to have rates of hospitalization similar to their pre-HAART initiation rates for about 45 days after HAART initiation. As a result primarily of a fall in infectious illness, responders' hospitalization rates then decrease to the clinic population-wide baseline rate by about 90 days after HAART initiation. This pattern occurred independently of CD4 cell count at HAART initiation and independently of having a large increase in CD4 cell count at 6 months. Clinicians should maintain a high degree of vigilance over patients until at least 90 days.
